Abstract
Latent inhibition (LI) is a behavioural phenomenon whereby preexposure to a stimulus without reinforcement interferes with the formation of subsequent associations to that stimulus. Using preexposure to a tone stimulus which subsequently serves as a conditioned stimulus for suppression of licking, we have confirmed that LI is disrupted by a low dose of amphetamine. Haloperidol was able to prevent this effect of amphetamine. Ondansetron, a selective and potent 5HT3 receptor antagonist, was also shown to be effective at blocking the amphetamine-induced disruption of LI at a dose of 0.01 mg/kg, but not at 0.1 mg/kg. In addition, it was demonstrated that ondansetron could enhance LI; using only ten preexposures, no LI was obtained in the saline group, but was apparent in animals given ondansetron, an effect which has been previously shown with haloperidol. Haloperidol, at the higher dose used, reduced suppression of licking, however, ondansetron at the effective dose had no such effect. It is concluded that ondansetron is able to attenuate increases in dopamine activity, produced pharmacologically with amphetamine without affecting baseline dopamine activity. The implications of these findings for a possible antipsychotic action of ondansetron are discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anscombe R (1987) The disorder of consciousness in schizophrenia. Schizophr Bull 13 [2]:241–260
Asarnow RF, Marder SR, Mintz J, Van Putten T, Zimmerman KE (1988) Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities. Arch Gen Psychiatry 45:822–826
Barnes JM, Costall B, Coughlan J, Domeney AM, Gerrard PA, Kelly ME, Naylor RJ, Onaivi ES, Tomkins DM, Tyers MB (1990) The effects of ondansetron, a 5HT3 receptor antagonist, on cognition in rodents and primates. Pharmacol Biochem Behav 35:955–962
Baruch I, Hemsley DR, Gray JA (1988) Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 176:598–606
Braff DL, Sacuzzo DP (1982) Effect of antipsychotic medication on speed of information processing in schizophrenic patients. Am J Psychiatry 139:1127–1130
Butler A, Hill JM, Ireland SJ, Jordan CC, Tyers MB (1988) Pharmacological properties of GR38032F, a novel antagonist at 5HT3 receptors. Br J Pharmacol 94:397–412
Carlsson A (1988) The current state of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179–203
Christison GW, Atwater GE, Dunn LA, Kilts CD (1988) Haloperidol enhancements of latent inhibition. Relation to therapeutic action. Biol Psychiatry 23:746–749
Costall B, Domeney AM, Kelly ME, Naylor RJ, Tyers MB (1987a) Antipsychotic potential of GR38032F, a selective antagonist of 5HT3 receptors in the central nervous system. Br J Pharmacol 90:89P
Costall B, Domeney AM, Naylor RJ, Tyers MB (1987b) Effects of the 5HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 92:881–894
De Veaugh-Geiss J, McBain S, Cooksey P, Bell JM (1992) The effects of a novel 5HT3 antagonist ondansetron, in schizophrenia: Results from uncontrolled trials. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven, New York, pp 225–232
Dunn LA, Atwater GE, Christison GW, Kilts CD (1989) Latent inhibition as an animal model of antipsychotic activity. Soc Neurosci Abstr 15:109.11
Ellenbroek BA, Cools AR (1990) Animal models with construct validity for schizophrenia. Behav Pharmacol 1:469–490
Feldon J, Weiner I (1988) Long-term attentional deficit in nonhandled males: possible involvement of the dopaminergic system. Psychopharmacology 95:231–236
Feldon J, Weiner I (1991) The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats ability to ignore irrelevant stimuli. Biol Psychiatry 29:635–646
Gray JA, Feldon J, Rawlins JNP, Hemsley DR, Smith AD (1991) The neuropsychology of schizophrenia. Behav Brain Sci 14:1–84
Gray NS, Pickering AD, Hemsley DR, Dawling S, Gray JA (1992) Abolition of latent inhibition by 5 mg of amphetamine in man. Psychopharmacology 107:425–430
Hagan RM, Butler A, Hill JM, Jordan CC, Ireland SJ, Tyers MB (1987) Effect of the 5HT3 receptor antagonist, GR38032F, on responses to a neurokinin agonist into the ventral tegmental area of the rat brain. Eur J Pharmacol 138:303–305
Hemsley DR (1987) An experimental psychological model for schizophrenia. In: Hafner H, Gattaz WF, Janzavik W (eds). Search for the causes of schizophrenia. Springer, Berlin Heidelberg New York, pp 179–188
Hillegaert V, Ahlenius S, Magnusson O, Fowler CJ (1987) Repeated testing of rats markedly enhances the duration of effects producted by haloperidol on treadmill locomotion, catalepsy and a conditioned avoidance response. Pharmacol Biochem Behav 27:159–164
Jones BJ, Costall B, Domeney AM, Kelly ME, Naylor RJ, Oakley NR, Tyers MB (1988) The potential anxiolytic activity of GR38032F, a 5HT3 receptor antagonist. Br J Pharmacol 93:985–993
Joseph MH, Jones SH (1991) Latent inhibition and blocking: further consideration of their construct validity as animal models of schizophrenia. Commentary on Ellenbroek and Cools “Animal models with construct validity for schizophrenia.” Behav Pharmacol 2:521–526
Kilpatrick GJ, Jones BJ, Tyers MB (1987) Identification and distribution of 5HT3 receptors in rat brain using radioligand binding. Nature 330:746–748.
Kokkinidis L, Anisman H (1981) Amphetamine psychosis and schizophrenia: a dual model. Neurosci Biobehav Rev 5:449–461
Koulou M, Lappalaimen J, Hietala J, Sjoholm B (1990) Effects of chronic administration of ondansetron (GR38032F), a selective 5HT3 receptor antagonist on monoamine metabolism in mesolimbic and nigrostriatal dopaminergic neurons and on striatal receptor binding. Psychopharmacology 101:168–171
Lubow RE (1973) Latent inhibition. Psychol Bull 79: 398–407
Lubow RE (1989) Latent inhibition and conditioned attention theory. Cambridge University Press, Cambridge
Lubow RE, Weiner I, Schnur P (1981): In: Bower GH (ed) The psychology of learning and motivation, vol 15. Academic Press, New York, pp 1–49
Lubow RE, Weiner I, Schlossberg A, Baruch I (1987) Latent inhibition and schizophrenia. Bull Psychon Soc 25:464–467
Mackintosh NJ (1983) Conditioning and associative learning. Oxford University Press, London
McGhie A, Chapman J (1961) Disorders of attention and perception in early schizophrenia. Br J Med Psychol 34:103–116
Meltzer HY (1991) Studies of ondansetron in schizophrenia. Satellite Symposium of 5th World Congress of Biological Psychiatry, Florence, Italy. The role of ondansetron, a novel 5HT3 antagonist, in the treatment of psychiatric disorders.
Moran PM, Moser PC (1992) MDL 73,147EF, a 5HT3 antagonist facilitates latent inhibition in the rat. Pharmacol Biochem Behav 42:519–522
Pich EM, Samanin R (1986) Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental models of anxiety in rats: possible role of dopamine. Psychopharmacology 89:125–130
Silverstone PH, Johnson B, Cowan PJ (1992a) Does ondansetron attenuate amphetamine-induced behaviour in human volunteers? Psychopharmacology 107:140–141
Silverstone PH, Oldman D, Johnson B, Cowan PJ (1992b) Ondansetron, a 5HT3 receptor antagonist, partially attenuates the effects of amphetamine: a pilot study in healthy volunteers. Int Clin Psychopharmacol 7:37–44
Solomon PR, Crider A, Winkelman JW, Turi A, Kamer RM, Kaplan LJ (1981) Disrupted latent inhibition in rats with chronic amphetamine or haloperidol-induced supersensitivity. Relationship to schizophrenic attention disorder. Biol Psychiatry 16:519–537
Spohn HE, Lacoursiere RB, Thompson K, Coyne L (1977). Phenothiazine effects on psychological and psychopharmacological dysfunction in chronic schizophrenics. Arch Gen Psychiatry 34:633–644
Swerdlow N, Koob G (1987) Dopamine, schizophrenia, mania and depression: towards a unified hypothesis of cortico-striato-pallidothalamic function. Behav Brain Sci 10:197–245
Warburton EC, Feldon J, Weiner I, Gray JA, Joseph MH (1992) Antagonism of low dose amphetamine disruption of latent inhibition in rats by haloperidol and the 5HT3 antagonist ondansetron (abstract presented at the summer BAP meeting, York, 1991). J Psychopharmacol 6:110
Weiner I, Feldon J (1987) Facilitation of latent inhibition by haloperidol. Psychopharmacology 91:248–253
Weiner I, Lubow RE, Feldon J (1984) Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology 83:194–99
Weiner I, Lubow RE, Feldon J (1988) Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol Biochem Behav 30: 871–878
Weiner I, Shofel A, Feldon J (1990) Disruption of latent inhibition by low dose amphetamine is antagonised by haloperidol and apomorphine. J Psychopharmacol 4:255
Young AMJ, Gray JA, Joseph MH (1993) Latent inhibition of conditioned dopamine release in rat nucleus accumbens. Neuroscience 34:5–9
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Clea Warburton, E., Joseph, M.H., Feldon, J. et al. Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: Implications for a possible antipsychotic action of ondansetron. Psychopharmacology 114, 657–664 (1994). https://doi.org/10.1007/BF02244998
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244998